Emerald Mutual Fund Advisers Trust Has $593,000 Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Emerald Mutual Fund Advisers Trust reduced its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 92.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,408 shares of the medical device company's stock after selling 230,096 shares during the quarter. Emerald Mutual Fund Advisers Trust's holdings in AtriCure were worth $593,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. bought a new position in AtriCure in the fourth quarter worth $9,168,000. Kennedy Capital Management LLC lifted its holdings in shares of AtriCure by 29.8% during the 4th quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after acquiring an additional 172,648 shares during the period. Marshall Wace LLP boosted its position in shares of AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after acquiring an additional 167,476 shares in the last quarter. Oberweis Asset Management Inc. bought a new stake in AtriCure in the fourth quarter valued at about $4,630,000. Finally, Dimensional Fund Advisors LP raised its position in AtriCure by 24.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock worth $21,398,000 after purchasing an additional 136,015 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ATRC shares. Canaccord Genuity Group lowered their price objective on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. UBS Group dropped their price objective on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday. JMP Securities reissued a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a report on Wednesday. Piper Sandler upped their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus lifted their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $50.67.

AtriCure Trading Up 2.5 %

ATRC stock traded up $0.73 during midday trading on Friday, reaching $30.02. The stock had a trading volume of 855,143 shares, compared to its average volume of 655,816. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -31.60 and a beta of 1.65. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $33.57 and a two-hundred day simple moving average of $34.68.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The company had revenue of $123.62 million during the quarter, compared to analysts' expectations of $122.92 million. During the same quarter in the previous year, the company earned ($0.28) EPS. AtriCure's revenue was up 13.5% on a year-over-year basis. As a group, research analysts expect that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company's stock, valued at $679,603.36. This represents a 25.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 3.50% of the company's stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.